GX-BP1 / Genexine - LARVOL DELTA

Lung-Targeted mRNA-LNP Delivery of SOX2 Bioprotac: A Comprehensive Strategy for LUAD, LUSC, and SCLC in Monotherapy and Combination Settings (IASLC-WCLC 2026) - "While Osimertinib monotherapy resulted in tumor relapse in EGFR-mutant LUAD model, the combination with SOX2 bioPROTAC successfully prevented recurrence, demonstrating complete eradication of CSCs. Conclusions : Our bioPROTAC platform converges to make SOX2, once considered undruggable, into a clinically viable therapeutic target. Our novel SOX2 bioPROTAC exerts superior anti-tumor efficacy through multi-faceted mechanisms, positioning them as optimal therapeutic candidates for patients who face challenges in treatment due to the limitations of existing therapies."

Monotherapy • Head and Neck Cancer • Lung Cancer • Small Cell Lung Cancer • Solid Tumor • Targeted Protein Degradation • HER-2 • SOX2

Genexine…announced that Jaehyun Choi, Ph.D., CEO and Head of R&D, presented new preclinical data for GX-BP1, the company’s SOX2-targeting bioPROTAC, at the 2026 World Conference on Lung Cancer (WCLC) (Businesswire) - "In an HCC827 EGFR-mutant lung cancer xenograft model, osimertinib initially produced strong tumor control, but tumors began to regrow after treatment ended at day 20. The combination of osimertinib and Dato-DXd delayed regrowth, but tumors eventually progressed from day 40 and showed significant volume after day 70. In contrast, osimertinib plus GX-BP1 combination therapy maintained durable tumor control for more than 100 days, with no substantial tumor regrowth observed during the study period. Most notably, the triple combination of GX-BP1, osimertinib and Dato-DXd achieved complete responses in all six animals (6/6 CR) with no regrowth observed."

Preclinical • Non Small Cell Lung Cancer • Small Cell Lung Cancer

Genexine Advances First In Class SOX2 Targeting BioPROTAC GX BP1 With Strong Preclinical Anti Tumour Data (BioPharma APAC) - "Preclinical data demonstrated strong anti-tumor activity across multiple models. GX-BP1 monotherapy achieved approximately 70% tumor growth inhibition (TGI), confirming meaningful standalone efficacy...In combination settings, GX-BP1 restored sensitivity in chemotherapy-resistant models and enhanced the efficacy of EGFR-targeted therapies, including osimertinib, by suppressing SOX2-driven resistance mechanisms...Notably, the combination of GX-BP1 with carboplatin and paclitaxel showed a clear dose-dependent response, achieving 87% to 96% TGI, with near-complete tumor growth suppression at higher doses. In addition, while tumor regrowth was observed in the osimertinib monotherapy group, the combination of GX-BP1 with osimertinib completely prevented tumor relapse, accompanied by effective elimination of cancer stem cell populations."

Preclinical • Solid Tumor

Genexine…announced new preclinical data for its SOX2-targeting bioPROTAC candidate, GX-BP1, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Businesswire) - "Preclinical data demonstrated strong anti-tumor activity across multiple models. GX-BP1 monotherapy achieved approximately 70% tumor growth inhibition (TGI), confirming meaningful standalone efficacy....Notably, the combination of GX-BP1 with carboplatin and paclitaxel showed a clear dose-dependent response, achieving 87% to 96% TGI, with near-complete tumor growth suppression at higher doses. In addition, while tumor regrowth was observed in the osimertinib monotherapy group, the combination of GX-BP1 with osimertinib completely prevented tumor relapse, accompanied by effective elimination of cancer stem cell populations."

Preclinical • Solid Tumor

Novel SOX2-targeting bioPROTACs as multi-faceted anti-tumor agents overcoming resistance to standard therapies in lung cancers (AACR 2026) - "Finally, we developed the clinically applicable drug product by utilizing a lung-targeted lipid nanoparticle (LNP), and confirmed its potent anti-tumor efficacy upon intravenous injection into an orthotopic lung cancer model. Taken together, our novel SOX2 bioPROTACs exert superior anti-tumor efficacy through multi-faceted mechanisms, positioning them as optimal therapeutic candidates for patients who face challenges in treatment due to the limitations of existing therapies."

Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2 • SOX2

Genexine, Non-small cell lung cancer new drug development 'GX-BP1' key technology international patent [Google translation] (Medipana) - "Genexine...announced on the 26th that it has completed an international patent PCT (Patent Cooperation Treaty) application for the key technology included in GX-BP1, which is being developed as a treatment for non-small cell lung cancer....The patent in question is an international patent for 'a single-domain antibody specifically binding to SOX2, a fusion protein comprising the same, and uses thereof' and includes a nanobody showing excellent binding affinity to SOX2 and an E3 ligase material optimized for SOX2 degradation."

Patent • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Genexine Shares Results of Lung Cancer...at US TPD Summit [Google translation] (HIT News) - "In this presentation, Vice President Choi disclosed key in vitro results of the bioprotactic pipeline GX-BP1 targeting the SOX2 protein, and shared the in vivo experimental results that demonstrated tumor growth inhibition and high degradation efficacy against intratumoral SOX2 protein in a xenograft animal model."

Preclinical • Lung Cancer • Oncology • Solid Tumor

Genexine, EPD Bio merger… “Bioprotac new drug development begins in earnest” [Google translation] (Medipana) - "Genexine...announced on the 2nd that it has completed its merger with EPD Biotherapeutics Inc. The company decided to merge with EPD Bio at a board meeting held on June 26th, and signed a merger agreement on July 1st. The merger new stock listing date is scheduled for October 17th...Through this merger, Genexine will acquire EPDeg, a bioPROTAC platform technology that can overcome the limitations of PROTAC...a representative technology in the TPD field, as well as innovative new pipelines and EPD Bio’s key research personnel with many years of industry experience...The pipeline that will enter the clinical stage the fastest is GX-BP1 (SOX2 bioPROTAC) targeting 'SOX2', a cancer-causing transcription factor...Genexine is proceeding with preclinical sample production this year and aims to apply for a domestic phase 1 clinical trial plan (IND) by the end of next year based on the animal testing results...In addition, Genexine is developing GX-BP2..."

M&A • New P1 trial • Atopic Dermatitis • Immunology • Lung Cancer • Oncology • Solid Tumor